Since its spinoff from Abbott Laboratories (NYSE:ABT) in 2013, AbbVie (NYSE:ABBV) has become one of the hottest big biotech stocks on the market. When AbbVie was formed, its market cap was close to Abbott’s. Now, however, the biotech’s market cap is nearly 35% higher than that of its parent company.
